Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus insulin glargine for glycemic control with minimal weight gain in type 2 diabetes
2005-006164-59Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2006
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of exenatide and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Apr 2006; status: completed.
02
Drugs
exenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-006164-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006164-59.